Disease Progression and Resistance to BTK Inhibitors
Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, talk about disease progression on BTKi and what mechanisms of resistance can occur.
Case 3: Disease Management Considerations
The panel of experts share their treatment recommendations for a 64-year-old woman with RET wild-type metastatic MTC.
ZETA and EXAM Clinical Trial Data
Dr Marcia Brose reviews key efficacy and safety data from the phase 3 ZETA and EXAM clinical trials.
Case 3: RET Wild-Type Metastatic MTC
Marcia Brose, MD, presents the case of a 64-year-old woman with RET wild-type metastatic medullary thyroid cancer.
The Future of DLBCL Treatment
Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, consider potential treatment options for relapsed/refractory diffuse large B-cell lymphoma in the future.
Bispecific Antibody Therapy R/R DLBCL
Two experts examine bispecific antibody treatment use for relapsed/refractory diffuse large B-cell lymphoma.
Pralsetinib: MOA and ARROW Trial Data
Lori Wirth, MD, discusses the mechanism of action of pralsetinib and key data from the phase 1/2 ARROW clinical trial.
Selpercatinib: Clinical Practice Implications
The panel of experts discuss practical considerations regarding selpercatinib and the LIBRETTO-001 and LIBRETTO-531 clinical trial data.
Selpercatinib: MOA and LIBRETTO Trial Data
Lori Wirth, MD, discusses the mechanism of action of selpercatinib and key data from the LIBRETTO-001 and LIBRETTO-531 clinical trials.
Case 2: Systemic Treatment Options
Experts in the management of thyroid cancer share their treatment recommendations for a 60-year-old man with RET+ metastatic medullary thyroid cancer.
Case 2: RET Mutations and Disease Management
The panel of experts discuss the importance of molecular testing and RET mutations in thyroid cancer disease management.
Case 2: RET+ MTC Disease Management
Dr Wirth reviews disease management considerations a 60-year-old man with RET+ metastatic medullary thyroid cancer.
TC Patient Considerations: Thyroidectomy
Lori Wirth, MD, and Andrew Gianoukakis, MD, discuss patient and clinical characteristics necessitating thyroidectomy in patients with thyroid cancer.
Case 2: RET+ Metastatic Medullary Thyroid Cancer
Lori Wirth, MD, presents the case of a 60-year-old man with RET+ metastatic medullary thyroid cancer.
Clinical Trials of BTKi in B-Cell Lymphomas
Drs Shadman and Cohen discuss clinical trial data utilizing acalabrutinib in B-cell lymphomas.
Comparing Ibrutinib, Acalabrutinib, and Zanubrutinib BTKi
Two experts compare experiences and data concerning use of ibrutinib, acalabrutinib, and zanubrutinib in B-cell lymphomas.
Lenvatinib: Dose Considerations
Marcia Brose, MD, discusses the efficacy and safety data of a phase 2 trial examining lenvatinib dose reductions in patients with RAI-DTC.
SELECT Trial: Post-Hoc Analysis
Andrew Gianoukakis, MD, and Lori Wirth, MD, examine post-hoc analysis data from the phase 3 SELECT trial.
Ibrutinib Clinical Trials for B-Cell Lymphomas
Drs Shadman and Cohen provide an overview of clinical trials utilizing the BTK inhibitor, ibrutinib, for B-cell lymphomas.
Available BTKi and Their Mechanisms of Action
Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, introduce available BTK inhibitors used as targeted therapy in B-cell malignancies.
CD19-Targeted mAbs in RR DLBCL Using Loncastuximab Tesirine
The doctors switch their monoclonal antibody conversation’s focus to longcastuximab tesirine for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
CD19-Targeted mAbs in R/R DLBCL Using Tafasitamab Continued
The discussion of tafasitamab as a monoclonal antibody therapy option for relapsed/refractory diffuse large B-cell lymphoma continues.
DTC Key Efficacy and Safety Data
Dr Andrew Gianoukakis reviews the study design and key efficacy data of the phase 3 DECISION and SELECT trials.
Thyroid Cancer Treatment Guidelines
Andrew Gianoukakis, MD, reviews the NCCN guidelines for the treatment of patients with thyroid cancer.
RR-DTC Systemic Therapy Considerations
Dr Andrew Gianoukakis, explores considerations surrounding systemic therapy in patients with RAI-refractory differentiated thyroid cancer.
RR-DTC: Molecular Testing Considerations
Marcia Brose, MD and Lori Wirth, MD, discuss molecular testing considerations in patients with radioiodine-refractory DTC.
RAI Treatment: Impact of Mutation Status
Experts in the management of thyroid cancer discuss radioactive iodine therapy and the clinical implications of mutational status in RAI- refractory DTC.
RR-DTC: Definition and Clinical Presentation
The panel of experts share their insights into the definition and clinical presentation of radioiodine-refractory DTC.
Case 1: Treatment Considerations for Refractory DTC
Andrew Gianoukakis, MD, reviews the treatment and management options for a 71-year-old woman with RAI- refractory differentiated thyroid cancer.
Case 1: Considerations of RAI Use
Experts in thyroid cancer discuss treatment considerations surrounding the use of radioiodine therapy in patients with thyroid cancer.